Introduction
Immunotherapy has become a major therapeutic strategy in oncology. Immune checkpoint inhibitors, such as cytotoxic T-lymphocyteassociated antigen 4 [1] [2] [3] non-small cell lung cancer, 4 renal cell carcinoma, 5 and recurrent squamous cell carcinoma of the head and neck. 6 However, one of their major limitations is the high incidence of immune-related adverse events [IrAEs] , especially enterocolitis. 5, 7 Data concerning the immunopathology of anti-CTLA-4-related colitis are scarce and, to our knowledge, are nonexistent for anti-PD-1-related colitis. It has been suggested that depletion of mucosal FoxP3 + CD4 + regulatory T cells [Treg] induced by αCTLA-4 treatment may elicit irAEs. 8 However, no mucosal or peripheral depletion of Treg was observed after αCTLA-4 treatment. 9 Management guidelines of IrAEs [10] [11] [12] based on clinical trials, small case series, and case reports have been published. [13] [14] [15] [16] [17] Their management is similar to that of inflammatory bowel disease [IBD] , despite there being no immunological or biological data showing that αCTLA-4-and αPD-1-induced colitis have a similar physiopathology.
Further recent approvals of immune checkpoint inhibitors in various cancers will lead to increasing numbers of patients exposed to these treatments and their toxicities. Thus, a better characterisation and understanding of the underlying mechanisms of immunotherapy-induced colitis is mandatory. T cells such as regulatory T cells, conventional CD4 + T cells, and CD8 + T cells, and T cell expression of inducible T-cell costimulator [ICOS] , were studied in patients developing colitis after CTLA-4 or PD-1 blockade. Indeed, previous studies suggested that blocking CTLA-4 induced activation, proliferation, and effector functions of regulatory T cells and conventional CD4 + T cells as well as up-regulation of ICOS. [18] [19] [20] Moreover, regulation of ICOS on regulatory T cells after CTLA-4 blockade can protect mice from developing colitis. 21 Considering the regulation of the PD-1/PD-L1 axis, previous studies in the tumour microenvironment have demonstrated that pre-existing CD8 + T cells are increased after anti-PD-1 blockade, inducing proliferative and cytotoxic activity associated with tumour regression. 22, 23 In this study, we provide histological description of αCTLA-4-and αPD-1-induced colitis, and analysed in colon biopsies conventional and regulatory CD4 + T cells, CD8 + T cells and ICOS expression within T cell populations.
Patients and Methods

Patients
In this prospective study, we enrolled consecutive patients with αCTLA-4-and αPD-1-induced colitis between May 2013 and July 2015. The majority of patients were recruited at Gustave Roussy IgG4] were administered intravenously every 2 and 3 weeks, at a dose of 3 mg and 2 mg per kilogram, respectively. Sociodemographic, clinical, biological, and endoscopic data were recorded using prespecified case report forms. Colonic biopsy samples were collected to assess T cell infiltration and cytokine secretion.
All patients enrolled in this study signed an informed consent form before any study procedures [GOLD study: SC12-018; ID-RCB-2012-6 A01496-37; CA184-169 2011-004029-28 study: NCT01515189; MelIpiRx study: EUDRACT 2010-020317-93; GEFTREM study: NCT02040064; and KEYNOTE-013 study: NCT01953692]. All procedures were performed in accordance with the Declaration of Helsinki.
Flow cytometry
Fresh colon biopsies were collected during endoscopy examination for 17 patients with αCTLA-4-, 5 αPD-1-induced colitis, and four patients with IBD. An enzymatic digestion was performed using Pulmozyme® [Roche] 
Immunohistochemistry
The colonic biopsies of patients were provided by the Kremlin Bicêtre hospital. An expert gastrointestinal pathologist at Gustave Roussy performed pathological examination of biopsy specimens in 25 αCTLA-4-induced colitis cases, five αPD-1-induced colitis cases, and four IBD cases. Serial sections from paraffin-embedded biopsies were stained with haematoxylin-eosin-saffron [ ], five αPD-1-induced colitis cases, and ffffour IBD cases. For FoxP3, staining detection was performed using an HQ amplification kit in the Ventana Discovery Ultra platform and Discovery purple was used as a chromogen. For CD3, CD8, and CD20 staining, an UltraView detection kit in the Ventana Benchmark Ultra platform and the 3,3'-diaminobenzidine chromogen were used. The number of stained cells was manually counted under the supervision of a pathologist, blinded from the clinical data. For each slide, two to three high power fields were extracted from virtual slides and cell counting was performed with ImageJ software using the Cell Counter plugin.
Statistical analysis
Continuous variables are presented as medians and ranges. Categorical variables are presented as percentages. Continuous data were analysed using the unpaired non-parametric Mann-Whitney test for two groups or Kruskal-Wallis test for more than two groups. 
Results
Clinical characteristics of the patients
During the study period, 37 patients developed αPD-1-or αCTLA-4-induced colitis and were included at the time of colitis diagnosis. Among them, four patients were excluded from the analysis: one had received αCTLA-4 and αPD-1 simultaneously, one had a diverticulitis, and two patients had no available colonic biopsies. Among the 33 remaining patients, 27 
Histological picture of anti-CTLA-4-and anti-PD-1-induced colitis
Among the 33 patients who developed colitis following immune checkpoint blockade, immunohistology could be realised only in 25 αCTLA-4-and five αPD-1-induced colitis due to lack of material. All patients had histological features ranging from minimal to severe colitis; indeed, infiltrates of immune cells and epithelial lesions of variable intensity could be observed [ Figure 1A ]. Immune infiltrates comprised lymphocytes and plasma cells, usually diffusely distributed within the lamina propria, or sometimes grouped in loose aggregates. Intraepithelial lymphocyte exocytosis was common, usually being minimal and focal. In two cases, the density of intraepithelial lymphocytes [IELs] was comparable to that observed in lymphocytic colitis [> 20 IELs per 100 epithelial cells]. Activated lymphocytes with large nuclei were found in the two types of colitis. Among immune cells, variable numbers of eosinophils and macrophages were observed. Few neutrophils were present around crypts or within crypt lumina. Epithelial lesions included: minimal and patchy alterations of the surface epithelium; disorganisation and reduction in number of crypts; and scattered crypt abscesses [ Figure 1A ]. The lamina propria was usually oedematous; in some cases, patchy lesions of incipient fibrosis were present. Occasionally, dilated capillaries lined by plumped endothelial cells were present; the lumen of these capillaries was filled with mononuclear cells [ Figure 1A ].
Lymphocytes were the main immune cell population in αCTLA- 
Predominance of mucosal CD4
+ T cells in αCTLA-4-induced colitis and of mucosal CD8 + T cells in αPD-1-induced colitis
We next characterised more precisely the CD3 + infiltrate. By immunohistochemistry, the subepithelial layer was shown to be enriched with CD4 + T cells in αCTLA-4-induced colitis biopsies, whereas CD8 + T cells were predominant in αPD-1-induced colitis biopsies. Owing to epithelium destruction, we could only analyse the epithelium of 20/25 αCTLA-4-induced colitis biopsies. Interestingly, CD8 + IELs were observed in four patients [80%] with αPD-1-induced colitis, whereas intraepithelial CD8+ lymphocytes were observed in only three patients [12%] with αCTLA-4 induced colitis [ Figure 1C ].
The absolute count and the proportion of CD8 + T cells in colon biopsies were significantly higher in patients with αPD-1-induced 80 a n t i-C T L A -4 a n t i-P D -1 a n t i-C T L A -4 n = 2 5 a n t i-P D -1 n = 5 a n t i-C T L A -4 n = 2 5 a n t i-P D -1 n = 5 a n t i-C T L A -4 n = 1 7 a n t i-P D -1 n = 5 a n t i-C T L A -4 n = 1 7 a n t i-P D -1 n = 5 receiving Figure 1E ]. 24 Since Treg are enriched in the colonic mucosa of patients with active IBD, 25 we also analysed FoxP3 + cells in four patients with an active IBD before any treatment, as controls. 
No depletion
of colonic regulatory T lymphocytes following αCTLA-4 or αPD-1 treatments Regulatory T lymphocytes [Treg] harbour high levels of CTLA-4 and PD-1 and may therefore be targeted by anti-CTLA-4 and anti-PD-1 antibodies in these treatments. Previous studies showed that Treg may be depleted in tumour or colon tissue following αCTLA-4 immunotherapy.
Inducible T-cell CoStimulator [ICOS]
+ CD4 + T lymphocytes were mainly FoxP3 -CD4 + T cells in αCTLA-4-induced colitis.
We monitored ICOS on T cells because previous studies had demonstrated that it could be related to clinical response. [26] [27] [28] In mouse models, previous studies suggested that ICOS could also play a major role in the induction of αCTLA-4-induced colitis. 21 We looked at ICOS expression in mucosal colonic T cells in 14 Figure 3] . In conclusion, the number of activated ICOS + Tconv cells was higher in αCTLA-4-induced colitis.
3.6. TNFα secretion is significantly higher in αCTLA-4-induced colitis than in αPD-1-induced colitis.
Anti-TNFα [infliximab] is used in the treatment of steroid-refractory αCTLA-4-induced colitis. 12 We analysed TNFα concentrations within colonic biopsies collected before steroid treatment in 30 patients [20 patients treated with αCTLA-4, six patients treated with αPD-1, and four IBD patients]. Mucosal TNFα was significantly higher in αCTLA-4-induced colitis biopsies (median value 222 pg/ml [0−4721]) than in αPD-1-induced colitis biopsies (median value 0 pg/ml [0−60]; p = 0.0075) or IBD patient biopsies (median value at 0 pg/ml [0−271]; p = 0,0634) [ Figure 3A ]. Five patients were treated with symptomatic treatments for their colitis, and no mucosal TNFα was detected in these patients. Of the 25 patients who received corticosteroids, 13 had low concentrations of mucosal TNFα [median value ≤ 61.5 pg/ml] and all had a clinical remission under steroid treatment. Among the 12 patients with high concentrations of mucosal TNFα [> 61.5 pg/ml], 50% were refractory to steroids and received second-line treatment with infliximab [ Figure 3B ]. Low mucosal concentrations of TNFα were systematically associated with clinical remission under corticosteroids [ Figure 3B ]. It is of note that no patient treated with αPD-1 required infliximab treatment, in accordance with their low TNFα concentrations [ Figure 3 ]. Altogether these results indicate that mucosal concentration of TNFα may predict steroid sensitivity.
Discussion
This study showed that αCTLA-4-and αPD-1-induced colitis have distinct immunological and pathological characteristics. Subjects with αCTLA-4-induced colitis had enriched colon mucosal CD4 + T cells, whereas subjects with αPD-1-induced colitis had substantial mucosal and intraepithelial CD8 + T cell populations. In addition, in αCTLA-4-induced colitis, the proportion of activated CD4 + T cells expressing ICOS was preferentially among conventional CD4+ T cells, whereas ICOS was predominantly expressed on regulatory CD4 + T cells in αPD-1-induced colitis and in IBD. High concentrations of mucosal TNFα were only observed in αCTLA-4-induced colitis. Finally, low mucosal TNFα concentrations were associated with steroid sensitivity in our patient cohort.
Microscopic colitis encompasses collagenous colitis and lymphocytic colitis. The diagnosis is based upon an endoscopically normal mucosa and pathological abnormalities in biopsy specimens. Increased thickening of the subepithelial collagenous band [> 10 μm] is the key diagnostic factor of collagenous colitis, whereas an increased intraepithelial lymphocyte count [> 10-20 IELs per 100 epithelial cells] is the key diagnostic factor of microscopic or lymphocytic colitis. 29, 30 Colonic samples collected in αPD-1-induced colitis displayed patchy IEL foci whereas, in microscopic colitis, IEL foci are increased and more diffuse. 29, 30 Although all the patients with αPD-1-induced colitis had IEL infiltrates, in most cases a histological diagnosis of microscopic or lymphocytic colitis could not be made due to unfulfilled diagnostic criteria. In a recent case report, Baroudjian and colleagues described a collagenous colitis in a patient who had received pembrolizumab [αPD-1] after αCTLA-4 failure. 31 In our cohort, αPD-1-induced colitis was systematically associated with mucosal inflammation and infiltrates composed of CD8 + T cells including intraepithelial CD8 + T cells, but without collagen layer thickening. The lack of collagenous colitis observed in this study might be explained by the fact that no patients received αPD-1 treatment after αCTLA-4 treatment failure.
One of the limitations of this study was the control group. Patients receiving αCTLA-4 or αPD-1 without developing colitis would have been the best control; however, colonoscopy in asymptomatic patients was not ethically allowed. αCTLA-4-related colitis has some resemblance to IBD, such as patchy areas of inflammation, localisation to rectum; colon; ileum; duodenum; and lymphocytic infiltrate. 15, 32 Further, in IBD, systemic steroids and/or infliximab treatment are used to reach clinical response. 13, 32 However, the pattern of ipilimumab-induced serological markers (perinuclear antineutrophil cytoplasmic antibodies [pANCA] and antibodies to porin protein C of Escherichia coli [OmpC] ) and the histological features of the inflammation were distinct from classical IBD. 32 Previous histological studies described features of acute colitis with crypt abscesses in αCTLA-4-related colitis. 13, 15, 32 Contrary to Verschuren et al., we did not observe, in this cohort, crypt irregularities often associated with chronic disease such as IBD.
14 Taken together, αPD-1-induced colitis shares some but not all pathological similarities with microscopic colitis, and αCTLA-4-induced colitis shares some but not all pathological features of IBD. Moreover, our results suggest that distinct immune mechanisms might be implicated in the induction and/or maintenance of inflammation in αCTLA-4-and in αPD-1-induced colitis.
We observed that αCTLA-4-related colitis was enriched with CD4 + T cells whereas CD8 + T cells were augmented in αPD-1-induced colitis. CTLA-4 is expressed on CD4 + T cells, and particularly on Treg cells. Blocking CTLA-4 using αCTLA-4 antibodies induces activation, proliferation, and effector functions in CD4 + T cells. 18, 19, 33 the PD-1/PD-L1 axis in the tumour microenvironment represents a potent immune escape mechanism that blocks antigen-specific CD8 + T cells. 22 Previous studies in the tumour microenvironment have demonstrated that pre-existing CD8 + T cells are increased after PD-1 blockade, and that these cells have increased proliferative and cytotoxic functions. 23 Interestingly, CD8 + T cells were predominant in biopsies of αPD-1-induced colitis, suggesting this population to be the main T cell actors in αPD-1-induced colitis contrary to αCTLA-4-induced colitis. A recent meta-analysis of the risk of irAE in patients treated with αCTLA-4 or αPD-1 demonstrated that the spectrum of inflammatory adverse events is very different between these therapies. 34 This seems consistent with our data suggesting that immune mechanisms involved may be different.
Treg harbour high levels of CTLA-4 35, 36 and intermediate levels of PD-1. 37 In our study, no depletion in mucosal Treg seemed to be observed in immunohistochemistry and flow cytometry analysis. This is in accordance with a previous study in which no evidence of Treg reduction was observed after αCTLA-4 treatment. 9 Activated T cells were present in virtually all the biopsies, and might have reflected the activation of immune cells. Conversely, high numbers of ICOS + conventional CD4 + T cells were observed only in αCTLA-4-induced colitis. In a mouse model, an increase in ICOS expression was described, mainly on Treg after blockade of CTLA-4. In this model, ICOS + Treg could inhibit memory Th1 responses in an IL-10-dependent manner, and could repress experimental intestinal inflammation. 21 In the same study, CTLA-4 blockade was protective, could improve trinitrobenzene sulphonic acid [TNBS]-induced colitis, and αCTLA-4 injection was associated with a high frequency of ICOS + Treg within ICOS + CD4 + T cells. 21 Thus mice never developed clinical colitis after CTLA-4 blockade, which is a major difference as compared with some patients treated with αCTLA-4 therapies. Thus, the balance of effector/regulatory T cells within ICOS + T cells suggests predominance of pro-inflammatory T cells after CTLA-4 blockade in patients with αCTLA-4-induced colitis. These results are reminiscent of previous studies in which ICOS induction on peripheral CD4 + T cells during ipilimumab treatment has been proposed as a biomarker of ipilimumab efficacy in patients with cancer. It must be noted that no imbalance between Treg and Tconv expressing ICOS was observed in IBD patients or in patients treated with αPD-1, which further supports different immune-related mechanisms between αCTLA-4-and αPD-1-induced colitis.
Patients with αCTLA-4-and αPD-1-induced colitis may respond to steroids. Infliximab could be another option for the treatment of steroid-resistant αCTLA-4/αPD-1-induced colitis. Infliximab is theoretically contraindicated in patients with cancer. In this study, the level of TNFα protein in the mucosa was higher after CTLA-4 blockade compared with PD-1 blockade. Low mucosal TNFα concentrations were associated with steroid sensitivity. Schreiber and colleagues have showed, in a cohort of 137 patients with Crohn's disease, that increased intestinal secretion of TNFα and interleukin-1β was predictive of acute relapse within the following year. 38 Recently Atreya et al. described, in patients with Crohn's disease receiving infliximab, that the numbers of membrane-bound TNFα (mTNFα) cells had significantly higher short-term response rates to treatment as compared with patients with low amounts of mTNFα cells. 39 Thus, the level of mTNFα cells could serve as a predictive biomarker of clinical response to infliximab induction treatment. 39 In another study, Olsen et al. showed that high TNFα gene expression in colorectal mucosa was an inverse predictor of remission after induction therapy with infliximab in ulcerative colitis. 40 In our study, we measured TNFα protein concentration spontaneously released by colonic biopsies. Using this simple method, we observed that low concentrations of TNFα were associated with steroid sensitivity. High TNFα concentration was associated with 50% resistance to corticosteroids. The low level of mucosal TNFα detected in αPD-1-related colitis biopsies suggests that infliximab treatment might be less efficient at countering αPD-1-induced colitis than αCTLA-4-induced colitis. The small cohort of patients with αPD-1-induced colitis was a major limitation in this study, due to the poor relative incidence of this irAE. Further investigations in patients with αPD-1-induced colitis are therefore needed to validate our results.
In conclusion, this study suggests that αCTLA-4-and αPD-1-induced colitis are two distinct immunohistopathological entities. To our knowledge, this work is the first to highlight distinct inflammatory infiltrates between αCTLA-4-and αPD-1-induced colitis, suggesting a different immune mechanism. Although based on a limited number of patients, the reduced levels of mucosal TNFα in αPD-1-induced colitis biopsies suggest that infliximab might not be a good option in these patients, unlike patients with αCTLA-4-induced colitis.
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